CavatermTM vs TCRE in Women With DUB

NCT ID: NCT00549159

Last Updated: 2008-05-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

158 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of study is to compare the treatment success in the study groups.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study success will be defined as reduction of uterine bleeding evaluated by number of patients obtaining amenorrhea, hypomenorrhea or eumenorrhea quantified by PBLAC\<75.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dysfunctional Uterine Bleeding

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

menorrhagia dysfunctional uterine bleeding endometrial ablation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cavaterm

Group Type EXPERIMENTAL

Thermal Balloon Endometrial Ablation

Intervention Type DEVICE

Thermal balloon endometrial ablation

TCRE

Transcervical resection of the endometrium

Group Type ACTIVE_COMPARATOR

Transcervical Resection of the Endometrium

Intervention Type DEVICE

Transcervical resection of the endometrium

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Thermal Balloon Endometrial Ablation

Thermal balloon endometrial ablation

Intervention Type DEVICE

Transcervical Resection of the Endometrium

Transcervical resection of the endometrium

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willingness and adequate mental capacity to sign written, informed consent
* Willingness to adhere to study plan regarding control visits and recording of PBLAC
* \> 30 years old
* Pre-menopausal as determined by FSH ≤30
* Agree not to use hormonal contraception or any other intervention for bleeding during study
* Suitable for local and/or general anesthesia
* A minimum PBLAC score of ≥ 150 for three months prior to study enrollment; OR PBLAC score 150 for one month for women who 1) had at least 3 (documented) prior months of failed medical therapy; 2) had a contraindication to medical therapy; or 3) refused medical therapy
* Uterine cavity sound measurement ≥ 4 cm and ≤ 10 cm.

Exclusion Criteria

* Presence of bacteriaemia, sepsis, or other active systemic infection
* Active pelvic inflammatory disease
* Clotting defects or bleeding disorders
* Unwillingness to use a non-hormonal birth control post-ablation
* Desire for future fertility
* Abnormal cavity as confirmed by hysteroscopy, transvaginal ultrasound or HSG e.g. large fibroids, septum etc. Small submucosal fibroids defined as \< 2 cm are in this context not considered abnormal.
* Any condition leading to possible uterine wall weakness with total wall thickness \< 15 mm e.g. at c.section, postmyomectomy scars etc. In case of uniform uterine wall the wall thickness at the fundus should be measured.
* Premalignant or malignant uterine condition within the last five years as confirmed by histology
* Pregnancy
* Cervical length \> 6 cm.
* Uterine cavity \>30 ml defined as balloon can be filled with 30ml glucose solution without reaching the target pressure of 240 mmHg. (These patients may still be treated as planned but will be withdrawn from the study and their data will be analysed separately. The patients will be recorded as screening failures).
* Previous ablation or subtotal hysterectomy
Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pnn Medical A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pnn Medical A/S

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yanhong Yu, Prof.

Role: PRINCIPAL_INVESTIGATOR

Guangzhou Southern Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhu Jiang Hospital

Guangzhou, Guangdong, China

Site Status RECRUITING

Guangzhou Southern Hospital

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yanhong Yu, Prof.

Role: CONTACT

Phone: +862061641017

Email: [email protected]

Nan Liu, MD

Role: CONTACT

Phone: +8613889903451

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2006-0026-06 dd20070920

Identifier Type: -

Identifier Source: org_study_id